HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy
- 1 February 1999
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 52 (3) , 623
- https://doi.org/10.1212/wnl.52.3.623
Abstract
Article abstract Introduction of highly active antiretroviral therapy (HAART) has been associated with many changes in the complications of human immunodeficiency virus (HIV) infection. A cohort of 25 HIV patients with progressive multifocal leukoencephalopathy (PML) treated with HAART experienced a median survival of >46 weeks. This is an improvement in prognosis compared with recent historic experience and correlated with HIV RNA viral load reductions. We conclude that current HIV therapy is important in improving the outlook of PML in the setting of HIV.Keywords
This publication has 6 references indexed in Scilit:
- Progressive Multifocal Leukoencephalopathy, HIV, and Highly Active Antiretroviral TherapyNew England Journal of Medicine, 1998
- Predictive factors for prolonged survival in acquired immunodeficiency syndrome—associated progressive multifocal leukoencephalopathyAnnals of Neurology, 1998
- Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathyAIDS, 1998
- Failure of Cytarabine in Progressive Multifocal Leukoencephalopathy Associated with Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Progressive Multifocal Leukoencephalopathy in Patients with HIV InfectionJournal of NeuroVirology, 1998